This company listing is no longer active
0H7S Stock Overview
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Abiomed, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$381.02 |
| 52 Week High | US$381.38 |
| 52 Week Low | US$226.36 |
| Beta | 1.4 |
| 1 Month Change | 1.17% |
| 3 Month Change | 58.53% |
| 1 Year Change | 14.96% |
| 3 Year Change | 132.51% |
| 5 Year Change | n/a |
| Change since IPO | 59.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0H7S | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0.2% | 1.7% | 0.7% |
| 1Y | 15.0% | -9.2% | 3.0% |
Return vs Industry: 0H7S exceeded the UK Medical Equipment industry which returned -11.9% over the past year.
Return vs Market: 0H7S exceeded the UK Market which returned -9.6% over the past year.
Price Volatility
| 0H7S volatility | |
|---|---|
| 0H7S Average Weekly Movement | 16.0% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0H7S's share price has been volatile over the past 3 months.
Volatility Over Time: 0H7S's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 2,003 | Mike Minogue | www.abiomed.com |
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite.
Abiomed, Inc. Fundamentals Summary
| 0H7S fundamental statistics | |
|---|---|
| Market cap | US$17.19b |
| Earnings (TTM) | US$266.76m |
| Revenue (TTM) | US$1.07b |
64.4x
P/E Ratio16.0x
P/S RatioIs 0H7S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0H7S income statement (TTM) | |
|---|---|
| Revenue | US$1.07b |
| Cost of Revenue | US$200.59m |
| Gross Profit | US$873.51m |
| Other Expenses | US$606.74m |
| Earnings | US$266.76m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.91 |
| Gross Margin | 81.32% |
| Net Profit Margin | 24.84% |
| Debt/Equity Ratio | 0% |
How did 0H7S perform over the long term?
See historical performance and comparison